“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Mumbai, Baltimore, March 13, 2018: Pharma major Lupin announced the launch of its Tydemy™ Tablets (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg and Levomefolate Calcium, 0.451mg) having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Tydemy™ (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg & Levomefolate Calcium, 0.451mg) are the generic equivalents of Bayer HealthCare Pharmaceuticals Inc.’s Safyral® tablets. It is indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception.
Drospirenone, EE, Levomefolate Calcium, 3mg/0.03mg/0.451mg & Levomefolate Calcium, 0.451mg tablets had annual sales of approximately USD 22 million in the US (IQVIA January 2018).
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Paediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment. Lupin is the 11th and 7th largest generics pharmaceutical company by market capitalization (December 31st, 2017, Bloomberg) and revenues (September 30th, 2017, Bloomberg LTM) respectively.
The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT December 2017); 2nd largest Indian pharmaceutical company by global revenues (September 30th, 2017, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in Indian Pharmaceutical Market (IQVIA MAT December 2017). For the financial year ended 31st March, 2017, Lupin’s consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
VP – Corporate Communications
Ph: +91-22-66402531 / 8291013225
Head – Investor Relations
*Safe Harbor Statement
Safyral® tablets is a registered trademark of Bayer Aktiengesellschaft